In ovarian cancer, GBP1 protects cells from paclitaxel by associating with beta-tubulin and indoleamine 2,3-dioxygenase 1 (IDO-1), enhancing survival under chemotherapeutic stress and enabling drug resistance [19,20,22]. Here, IDO1 is linked to ovarian cancer.